Neurodegenerative disorders are one of the leading causes of death and disability across the world. Cerebroprotein hydrolysate is the drug offering new hopes to patients suffering from these disorders. Cerebroprotein hydrolysate has been found to be helpful in treatment of traumatic brain injury, acute stroke, dementia, and Alzheimer’s disease. Its dominance in the market is because of its different pharmacokinetic actions which help in faster nerve repair and growth than other neurotrophic agents. Cerebroprotein hydrolysate has been also used in the management of dementia with promising results. It is used for the treatment of brain injuries and neurodegenerative conditions ranging from mild to severe. Global Cerebroprotein Hydrolysate Market was valued at just under USD 500 million in 2019 and is expected to reach over USD 745 million in 2027, growing at a CAGR of over 9.3% during the forecast period.
By type, global Cerebroprotein Hydrolysate market is segmented into Injection and Oral solution. In 2019, global Cerebroprotein Hydrolysate market was dominated by injection segment with almost 57.5% share in total revenue generation. It is also expected to be the fastest growing segment over the forecast period and maintain its dominance. Injection as a liquid or hydrolyzed powder form contains cerebroprotein hydrolysate as an active ingredient. It works on the central nervous system and improves the metabolism of neuron and protects nerves from damage.
Download FREE Sample PDF of Global Cerebroprotein Hydrolysate Market: https://www.eonmarketresearch.com/sample/76621
Global Cerebroprotein Hydrolysate market is segmented on the basis of applications such as dementia, traumatic brain injury and Others. Use of dementia segment accounted for the largest revenue of over USD 225 million in the year 2019. However, traumatic brain injury segment is expected to exhibit fastest CAGR among all application segments.
There is no direct substitute for cerebroprotein hydrolysate. Recently, rapid technological advancements are seen across healthcare industry along with increasing healthcare expenditure and government funds. Thus, technological advancements may bring new substitutes with improved efficiency and lesser side effects. Also, recombinant DNA technology (RDT) may bring positive insights in the treatment of Alzheimer’s disease, cerebrovascular strokes, traumatic brain injury and vascular dementia owing to increasing prevalence of these disorders.
North America dominated the global Cerebroprotein Hydrolysate market with over 30% share in 2019. Asia Pacific is fastest growing regional market and is anticipated to overtake North America to become the largest market of Cerebroprotein Hydrolysate by the end of forecast period. Europe also holds the significant market share however, expected to witness moderate growth rate over the forecast period.
Customization of the Report: This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@eonmarketresearch.com), who will ensure that you get a report that suits your needs.
Major players in global Cerebroprotein Hydrolysate market include but not limited to Tianda Pharmaceuticals Limited, Sihuan Pharmaceutical Holdings Group Ltd., Titan Biotech Limited, Jeevan Chemicals & Pharmaceuticals, Hangzhou Huajin Pharmaceutical Co,.Ltd, Shenzhen Mellow Hope Pharm Industrial Co., Ltd and Others. The global Cerebroprotein Hydrolysate market is highly fragmented with top six players accounting for just over 30% share in the global market.
Segmentation:
Cerebroprotein Hydrolysate Market by Type, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
- Injection
- Oral solution
Cerebroprotein Hydrolysate Market by Application, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
- Dementia
- Traumatic brain injury
- Others
Buy This Premium Report: https://www.eonmarketresearch.com/buy/76621
Cerebroprotein Hydrolysate Market by Region, 2015 – 2027 Volume (Tons) and Revenue (USD Million)
North America
- United States
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Russia
- Italy
- Spain
Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Australia
Latin America
- Brazil
- Argentina
- Chile
- Peru
Middle East and Africa
- Egypt
- Saudi Arabia
- South Africa
- Turkey
- Israel
Cerebroprotein Hydrolysate Market by Company, 2018 – 2019 Volume (Tons) and Revenue (USD Million)
- Tianda Pharmaceuticals Limited
- Sihuan Pharmaceutical Holdings Group Ltd.
- Titan Biotech Limited
- Jeevan Chemicals & Pharmaceuticals
- Hangzhou Huajin Pharmaceutical Co,.Ltd
- Shenzhen Mellow Hope Pharm Industrial Co., Ltd
- Others
Do Inquiry Before Purchasing Report Here and Ask For Discount: https://www.eonmarketresearch.com/enquiry/76621
Explore Related Report:
- Primary Hyperoxaluria Drug Market
- Caries Detection Devices Market
- Dental Fittings Market
- Pediatric Wheelchairs Market
- Impact Testers Market
- Exosome Diagnostics and Therapeutics Market
About Us:
Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.
Contact Us:
Eon Market Research
Phone: +1 703 879 7090
Email: sales@eonmarketresearch.com
